OT01 | A PHASE 3 TRIAL OF OBINUTUZUMAB AND VENETOCLAX WITH OR WITHOUT ACALABRUTINIB IN PATIENTS WITH HIGH RISK CHRONIC LYMPHOCYTIC LEUKEMIA: CLL16 TRIAL OF THE GCLLSG
Hematological Oncology · 2025-06 · 43 (S3)
DOI: 10.1002/hon.70093_ot01 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hematological Oncology, online erschienen am 16.06.2025. Verfasst von N. Kutsch und 19 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Kutsch, N., Robrecht, S., Zhang, C., Rathkolb, V., Damm, F., Wirths, S., Dierks, C., Gaska, T., Schoettker, B., Neumann, C., Hensel, M., Schneider, C., Tausch, E., Fischer, K., Kreuzer, K., Ritgen, M., Stilgenbauer, S., Hallek, M., Eichhorst, B., & Fink, A. (2025). OT01 | A PHASE 3 TRIAL OF OBINUTUZUMAB AND VENETOCLAX WITH OR WITHOUT ACALABRUTINIB IN PATIENTS WITH HIGH RISK CHRONIC LYMPHOCYTIC LEUKEMIA: CLL16 TRIAL OF THE GCLLSG. Hematological Oncology, 43(S3). https://doi.org/10.1002/hon.70093_ot01
Vancouver
Kutsch N, Robrecht S, Zhang C, Rathkolb V, Damm F, Wirths S, et al. OT01 | A PHASE 3 TRIAL OF OBINUTUZUMAB AND VENETOCLAX WITH OR WITHOUT ACALABRUTINIB IN PATIENTS WITH HIGH RISK CHRONIC LYMPHOCYTIC LEUKEMIA: CLL16 TRIAL OF THE GCLLSG. Hematological Oncology. 2025;43(S3). doi:10.1002/hon.70093_ot01
BibTeX
@article{Kutsch2025,
author = {Kutsch, N. and Robrecht, S. and Zhang, C. and Rathkolb, V. and Damm, F. and Wirths, S. and Dierks, C. and Gaska, T. and Schoettker, B. and Neumann, C. and Hensel, M. and Schneider, C. and Tausch, E. and Fischer, K. and Kreuzer, K. and Ritgen, M. and Stilgenbauer, S. and Hallek, M. and Eichhorst, B. and Fink, A.},
title = {OT01 | A PHASE 3 TRIAL OF OBINUTUZUMAB AND VENETOCLAX WITH OR WITHOUT ACALABRUTINIB IN PATIENTS WITH HIGH RISK CHRONIC LYMPHOCYTIC LEUKEMIA: CLL16 TRIAL OF THE GCLLSG},
journal = {Hematological Oncology},
year = {2025},
volume = {43},
number = {S3},
doi = {10.1002/hon.70093_ot01}
}
EUVIMED